Amy A. Lemke

Dr. Amy A. Lemke

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2015 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
ALAmy A. Lemke
Amy A. Lemke
JHJulie N. Harris-Wai
Julie N. Harris-Wai

1 September 2022 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ALAmy A. Lemke
Amy A. Lemke
EEEdward D. Esplin
Edward D. Esplin
AGAaron J. Goldenberg
Aaron J. Goldenberg
CGClaudia Gonzaga-Jauregui
Claudia Gonzaga-Jauregui
NHNeil A. Hanchard
Neil A. Hanchard
NGNanibaa’ A. Garrison
Nanibaa’ A. Garrison

2 August 2017 in Personalized Medicine
Verified
Journal Article
Open access
ALAmy A. Lemke
Amy A. Lemke
CSChristina G Hutten Selkirk
Christina G Hutten Selkirk
NGNicole S Glaser
Nicole S Glaser
ASAnnette W Sereika
Annette W Sereika
DWDyson T Wake
Dyson T Wake
HDHenry Dunnenberger
Henry Dunnenberger
Aim: To explore primary care physicians’ views of the utility and delivery of direct access to pharmacogenomics (PGx) testing in a community health system. Methods: This descriptive study assessed the perspectives of 15 healthcare providers utilizing qualitative individual interviews. Results: Three main themes emerged: perceived value and utility of PGx testing; challenges to implementation in practice; and provider as well as patient needs. Conclusion: While providers in this study viewed benefits of PGx testing as avoiding side effects, titrating doses more quickly, improving shared decision-making and providing psychological reassurance, challenges will need to be addressed such as privacy concerns, cost, insurance coverage and understanding the complexity of PGx test results.

22 February 2018 in Pharmacogenomics
Verified
Journal Article
Open access
ALAmy A. Lemke
Amy A. Lemke
PHPeter Hulick
Peter Hulick
DWDyson T Wake
Dyson T Wake
CWChi Wang
Chi Wang
ASAnnette W Sereika
Annette W Sereika
HDHenry Dunnenberger
Henry Dunnenberger
Aim: To assess patient perceptions and utilization of pharmacogenomics (PGx) testing in an integrated community health system. Methods: Fifty-seven patients completed an online survey assessing their experiences with PGx testing offered through two methods: a designated PGx clinic or direct access in-home testing. Results: The majority of participants perceived PGx testing as helpful in their healthcare and reported understanding their results. Some had concerns about privacy and discrimination; most lacked familiarity with the Genetic Information Nondiscrimination Act. There were no significant differences in views between participants tested through either model. Conclusion: Participants reported value in both methods of PGx testing. Patient experiences, understanding and result utilization will play an important role in informing future development and implementation of PGx programs.

15 February 2021 in Genetic Testing and Molecular Biomarkers
Verified
Journal Article
Open access
ALAmy A. Lemke
Amy A. Lemke
LALaura M. Amendola
Laura M. Amendola
JTJennifer Thompson
Jennifer Thompson
HDHenry M. Dunnenberger
Henry M. Dunnenberger
KKKristine Kuchta
Kristine Kuchta
PHPeter J. Hulick
Peter J. Hulick
Aims: To explore patient experiences in a large-scale primary care-based, preemptive genetic testing program. Methods: Patients who received genetic results from the initiative were invited to participate in an online survey 3 weeks postresult disclosure. A 6-month follow-up survey was sent to assess changes over time. Results: The initial survey was completed by 1646 patients, with 544 completing the 6-month follow-up survey. The following outcomes were high overall: patient-reported understanding of results (cancer: 87%; cardiac: 86%); perceived utility (75%); positive emotions (relieved: 66.8%; happy: 62.0%); family result sharing (67.6%); and satisfaction (87%), although analysis by demographic factors identified groups who may benefit from additional education and emotional support. Results-related health behaviors and discussions with providers increased over time (screening procedures 6.1% to 14.2% p < 0.001; provider discussion 10.3% to 25.3%, p < 0.001), and were more likely to take place for patients with positive cancer and/or cardiac results (39.8% vs. 7.6%, p < 0.001). Forty-seven percent of patients reported insurance discrimination concerns, and most (79.4%) were not familiar with privacy and nondiscrimination laws. Concerns regarding discrimination and negative emotions decreased between the two survey time points (privacy issues 44.6% to 35.1% p < 0.001; life insurance discrimination concerns 35.5% to 29.6%, p = 0.001; anxiety 8.1% to 3.3%, p < 0.001; and uncertainty 19.8% to 12.8%, p < 0.001). These findings led to the development and integration of additional patient resources to improve program implementation. Conclusion: Our findings highlight patient experiences with and areas of need in a community-based genomic screening pilot initiative using a mixed primary care/genetics provider model to deliver precision medicine.

Verified
Journal Article
Open access
PDF file
ALAmy A. Lemke
Amy A. Lemke
LALaura Amendola
Laura Amendola
KKKristine Kuchta
Kristine Kuchta
HDHenry Dunnenberger
Henry Dunnenberger
JTJennifer Thompson
Jennifer Thompson
PHPeter Hulick
Peter Hulick
The scalable delivery of genomic medicine requires collaboration between genetics and non-genetics providers. Thus, it is essential to investigate and address the perceived value of and barriers to incorporating genetic testing into the clinical practice of primary care providers (PCPs). We used a mixed-methods approach of qualitative interviews and surveys to explore the experience of PCPs involved in the pilot DNA-10K population genetic testing program. Similar to previous research, PCPs reported low confidence with tasks related to ordering, interpreting and managing the results of genetic tests, and identified the need for additional education. PCPs endorsed high levels of utility for patients and their families but noted logistical challenges to incorporating genetic testing into their practice. Overall PCPs were not familiar with the United States’ Genetic Information Nondiscrimination Act and they expressed high levels of concern for patient data privacy and potential insurance discrimination. This PCP feedback led to the development and implementation of several processes to improve the PCP experience with the DNA-10K program. These results contribute to the knowledge base regarding genomic implementation using a mixed provider model and may be beneficial for institutions developing similar clinical programs.